RespireRx Pharmaceuticals Inc (RSPI): Easily with partnership/funding to furth...

Reply Private New

Replies (1) Next 10 Prev Next

Send PM Follow Ignore

Followers	16
Posts	645
Boards Moderated	0
Alias Born	03/01/2024

LTListener

Re: LEFTY1182 post# 45098

Monday, 04/01/2024 8:54:23 AM

Monday, April 01, 2024 8:54:23 AM

Easily with partnership/funding to further their pain/epilepsy drug candidate post-NIH final preclinical trials. That would only be a 40 mil market cap now. Even if OS doubles, 80 mil market cap would seem very cheap considering the implications of success in mitigating opioid crisis as well as the size of that market…

There is just not clear visibility of timing of “possible” success there, nor timeline status of other programs like OSA. Could be 6 days or 6 months or longer? I am content accumulating.

Keep Last Read

Replies (1) Next 10 Prev Next

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:

Detailed Quote

Recent RSPI News

Form 8-K - Current report • Edgar (US Regulatory) • 09/06/2024 12:45:11 PM
Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 12:30:23 PM
Form 8-K - Current report • Edgar (US Regulatory) • 07/08/2024 08:01:32 PM
Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 01:03:20 PM
Form 8-K - Current report • Edgar (US Regulatory) • 02/02/2024 01:30:27 PM
Form 8-K - Current report • Edgar (US Regulatory) • 01/22/2024 01:45:38 PM
Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 01:45:18 PM
Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/17/2023 09:06:03 PM
Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/14/2023 09:05:14 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 01:00:21 PM
Form 8-K - Current report • Edgar (US Regulatory) • 10/02/2023 12:45:26 PM